Amy Claxton, Ph.D.
Affiliations: | 2010 | Psychology | University of Massachusetts, Amherst, Amherst, MA |
Area:
Clinical Psychology, Individual and Family Studies, Ethnic and Racial StudiesGoogle:
"Amy Claxton"Mean distance: 21373.2
Parents
Sign in to add mentorMaureen Perry-Jenkins | grad student | 2010 | U Mass Amherst | |
(Intersecting contexts: An examination of social class, gender, race, and depressive symptoms.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Lauriello J, Claxton A, Du Y, et al. (2020) Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study. The Journal of Clinical Psychiatry. 81 |
Craft S, Tripputi M, Edelstein S, et al. (2020) 1268-P: Associations between ß-Cell Function and Cognitive Measures following Treatment in Youth with Impaired Glucose Tolerance (IGT) or Recently Diagnosed Type 2 Diabetes (T2D) Diabetes. 69 |
Weiden PJ, Claxton A, Du Y, et al. (2019) 63 Long-term Outcomes with Aripiprazole Lauroxil for the Treatment of Schizophrenia: A 2-Year, Phase 3, Multicenter Extension Study. Cns Spectrums. 24: 208-209 |
Miller BJ, Claxton A, Du Y, et al. (2019) Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia Research |
Craft S, Claxton A, Tripputi M, et al. (2019) 1561-P: Associations between ß-Cell Function and Cognitive Measures Differ in Youth vs. Adults with Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes (T2D) Diabetes. 68 |
Craft S, Claxton A, Baker LD, et al. (2017) Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. Journal of Alzheimer's Disease : Jad |
Claxton A, Baker LD, Hanson A, et al. (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. Journal of Alzheimer's Disease : Jad. 44: 897-906 |
Claxton A, Baker LD, Wilkinson CW, et al. (2013) Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 35: 789-97 |
Claxton A, Baker L, Hanson A, et al. (2013) Long-acting intranasal insulin detemir improves working memory for adults with mild cognitive impairment or early-stage Alzheimer's dementia Alzheimers & Dementia. 9: 657 |
Craft S, Baker LD, Montine TJ, et al. (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Archives of Neurology. 69: 29-38 |